Glofitamab, a CD20/CD3 bispecific antibody, in the treatment of R/R DLBCL

The current and future role of bispecifics in R/R DLBCL: epcoritamab, glofitamab & moreПодробнее

Bispecific Antibody Treatment in Non-Hodgkin Lymphoma: Glofitamab - Blood Cancers OncTalk 2023Подробнее

The role of bispecific antibodies in the treatment landscape for R/R DLBCLПодробнее

Glofitamab as a SOC in third-line DLBCL and its potential in earlier lines of therapyПодробнее

Impact of TMTV on PFS following glofitamab treatment in R/R DLBCLПодробнее

The benefits of glofitamab in R/R DLBCL post-CAR-T therapyПодробнее

Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphomaПодробнее

Bispecific antibodies for R/R aggressive B-cell lymphomasПодробнее

Glofitamab in R/R DLBCL: updated safety and efficacy dataПодробнее

Phase II study of glofitamab in patients with R/R LBCLПодробнее

Insights into Phase I/II study assessing fixed-duration glofitamab treatment for R/R LBCLПодробнее

Updates in bispecifics for DLBCL from ASH: glofitamab, odronextamab, epcoritamab & mosunetuzumabПодробнее

Michael Dickinson, MBBS, DMedSc, on a Phase II Trial of Glofitamab in DLBCLПодробнее

Glofitamab and polatuzumab vedotin in DLBCLПодробнее

Updated results of glofitamab plus polatuzumab vedotin combination therapy in DLBCL, including HGBCLПодробнее

The important role of bispecific antibodies in the future treatment of R/R DLBCLПодробнее

Glofitamab as a single agent in heavily pretreated patients with DLBCLПодробнее

Efficacy of Epcoritamab and Glofitamab in Diffuse Large B-Cell LymphomaПодробнее

ASH highlights: glofitamab in DLBCL & pirtobrutinib and epcoritamab in Richter's transformationПодробнее

What is the rationale behind the combination of glofitamab + polatuzumab in patients with R/R DLBCL?Подробнее